Neuronal α-Synuclein Disease Stage Progression over 5 Years.

ABSTRACT:

Background

Neuronal α-synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha-synuclein (n-asyn) pathology. The NSD integrated staging system (NSD-ISS) for research describes progression across the disease continuum as stages 0 to 6.

Objective

The aim was to assess 5-year longitudinal change in NSD-ISS in early disease.

Methods

Analysis included a subset of participants from the Parkinson's Progression Markers Initiative (PPMI) enrolled before 2020 as Parkinson's disease (PD) patients, prodromal PD patients, or healthy controls (HC) who met NSD criteria. Staging was defined based on biomarkers of n-asyn and dopaminergic dysfunction in early stages, clinical features, and severity of functional impairment in stages 3 to 6. Stages we

SUBMITTER: Simuni T 

PROVIDER: S-EPMC12273616 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature